Post-diagnostic kinetics of the (1 → 3)-β-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia

Clinical Microbiology and Infection

Volumn 18, Issue 5, 2012, Pages

  Koo, S ^a,b,c   Baden, L R ^a,b,c   Marty, F M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Candidiasis; Galactomannan; Invasive aspergillosis; Invasive fungal disease; Kinetics; Pneumocystis jirovecii; glucan

Indexed keywords

(1-3) BETA DEXTRO GLUCAN; AMPHOTERICIN; ATOVAQUONE; CLINDAMYCIN; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; GLUCAN; PRIMAQUINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FEMALE; FOLLOW UP; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PICHIA; PICHIA OMERI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS;

PNEUMOCYSTIS JIROVECII;

EID: 84859919901     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03777.x     Document Type: Article

References (23)

1. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
2. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1 → 3) β-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
3. Senn L, Robinson JO, Schmidt S et al. 1, 3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-885.
4. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1 → 3)-β-d-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-1659.
5. Wiederhold NP, Najvar LK, Vallor AC et al. Assessment of serum (1 → 3)-β-d-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2008; 52: 1176-1178.
6. Kirkpatrick WR, Wiederhold NP, Najvar LK, et al. Treatment response in a Guinea Pig Model of Invasive Pulmonary Aspergillosis (IPA). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA 2009: Abstract M-447.
7. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
8. Marty FM, Koo S. Role of (1 → 3)-β-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 (suppl): S233-S240.
9. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-β-d-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1931.
10. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112: 2309-2312.
11. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.
12. Brown GD, Gordon S. Immune recognition of fungal β-glucans. Cell Microbiol 2005; 7: 471-479.
13. Suda M, Ohno N, Hashimoto T, Koizumi K, Adachi Y, Yadomae T. Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1 → 3)-β-d-glucan, SSG, in mice. FEMS Immunol Med Microbiol 1996; 15: 93-100.
14. Mitsutake K, Kohno S, Miyazaki T et al. Detection of (1 → 3)-β-d-glucan in a rat model of aspergillosis. J Clin Lab Anal 1995; 9: 119-122.
15. Hashimoto A, Yamakami Y, Kamberi P et al. Comparison of PCR, (1 → 3)-β-d-glucan and galactomannan assays in sera of rats with experimental invasive aspergillosis. J Clin Lab Anal 1998; 12: 257-262.
16. Cushion MT, Linke MJ, Ashbaugh A et al. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 2010; 5: e8524.
17. Pazos C, Ponton J, Del Palacio A. Contribution of (1 → 3)-β-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
18. Mikulska M, Furfaro E, Del Bono V et al. Persistence of a positive (1, 3)-β-d-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. Clin Vaccine Immunol 2011; 18: 518-519.
19. Watanabe T, Yasuoka A, Tanuma J et al. Serum (1 → 3) β-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49: 1128-1131.
20. Koga M, Koibuchi T, Kikuchi T et al. Kinetics of serum β-d-Glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med 2011; 50: 1397-1401.
21. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48: 1255-1260.
22. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
23. Prentice RL. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 2009; 101: 216-217.